Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PIK3CA | P42336 | 15/20 | 0.73 |
| ▸ | MTOR | P42345 | 5/20 | 0.73 |
| ▸ | PIK3CG | P48736 | 4/20 | 0.73 |
| ▸ | PIK3CD | O00329 | 3/20 | 0.73 |
| ▸ | PIK3C2B | O00750 | 2/20 | 0.73 |
| ▸ | PIK3CB | P42338 | 2/20 | 0.73 |
| ▸ | PIK3R1 | P27986 | 2/20 | 0.73 |
| ▸ | PIK3C2A | O00443 | 1/20 | 0.73 |
| ▸ | CHUK | O15111 | 1/20 | 0.73 |
| ▸ | DAPK3 | O43293 | 1/20 | 0.73 |
| ▸ | PIK3C2G | O75747 | 1/20 | 0.73 |
| ▸ | RAF1 | P04049 | 1/20 | 0.73 |
| ▸ | BRAF | P15056 | 1/20 | 0.73 |
| ▸ | CSNK2A2 | P19784 | 1/20 | 0.73 |
| ▸ | JAK1 | P23458 | 1/20 | 0.73 |
| ▸ | TYK2 | P29597 | 1/20 | 0.73 |
| ▸ | FLT3 | P36888 | 1/20 | 0.73 |
| ▸ | CLK1 | P49759 | 1/20 | 0.73 |
| ▸ | CLK2 | P49760 | 1/20 | 0.73 |
| ▸ | CLK3 | P49761 | 1/20 | 0.73 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15374748 | 0.87 | LMNA (0.67) | PIK3CAMTORPIK3CGPIK3CDPIK3C2B | |
| Pi-103 SCHEMBL258242 | 0.85 | PIK3CA (1.00) | PIK3CAMTORPIK3CGPIK3CDPIK3C2B | |
| Pi-103 SCHEMBL30387212 | 0.85 | PIK3CA (1.00) | PIK3CAMTORPIK3CGPIK3CDPIK3C2B | |
| Pi-103 SCHEMBL29929906 | 0.85 | PIK3CA (1.00) | PIK3CAMTORPIK3CGPIK3CDPIK3C2B | |
| Pi-103 SCHEMBL29676244 | 0.85 | PIK3CA (1.00) | PIK3CAMTORPIK3CGPIK3CDPIK3C2B | |
| Pi-103 SCHEMBL29352781 | 0.85 | PIK3CA (1.00) | PIK3CAMTORPIK3CGPIK3CDPIK3C2B | |
| Pi-103 SCHEMBL29527390 | 0.84 | PIK3CA (1.00) | PIK3CAMTORPIK3CGPIK3CDPIK3C2B | |
| SCHEMBL10092299 | 0.83 | PIK3CA (0.59) | PIK3CAMTORPIK3CGPIK3CDPIK3C2B | |
| SCHEMBL1309789 | 0.82 | ALDH1A1 (0.65) | PIK3CAMTORPIK3CGPIK3CDPIK3C2B | |
| SCHEMBL1311667 | 0.81 | LMNA (0.64) | PIK3CAMTORPIK3CGPIK3CDPIK3C2B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8921361-B2 | Triazine, pyrimidine and pyridine analogs and their use as therapeutic agents and diagnostic probes | UNIVERSITY OF BASEL (CH) | 2014-12-30 | — | — | US | claimed |
| US-20110275762-A1 | TRIAZINE, PYRIMIDINE AND PYRIDINE ANALOGS AND THEIR USE AS THERAPEUTIC AGENTS AND DIAGNOSTIC PROBES | UNIVERSITY OF BASEL (CH) | 2011-11-10 | — | — | US | claimed |
| EP-2364302-A2 | TRIAZINE, PYRIMIDINE AND PYRIDINE ANALOGS AND THEIR USE AS THERAPEUTIC AGENTS AND DIAGNOSTIC PROBES | University of Basel (CH) | 2011-09-14 | — | — | EP | claimed |
| WO-2010052569-A2 | TRIAZINE, PYRIMIDINE AND PYRIDINE ANALOGS AND THEIR USE AS THERAPEUTIC AGENTS AND DIAGNOSTIC PROBES | UNIVERSITY OF BASEL (CH) | 2010-05-14 | — | — | WO | claimed |
| US-8921361-B2 | Triazine, pyrimidine and pyridine analogs and their use as therapeutic agents and diagnostic probes | UNIVERSITY OF BASEL (CH) | 2014-12-30 | — | — | US | disclosed |
| US-8921361-B2 | Triazine, pyrimidine and pyridine analogs and their use as therapeutic agents and diagnostic probes | UNIVERSITY OF BASEL (CH) | 2014-12-30 | — | — | US | disclosed |
| US-8921361-B2 | Triazine, pyrimidine and pyridine analogs and their use as therapeutic agents and diagnostic probes | UNIVERSITY OF BASEL (CH) | 2014-12-30 | — | — | US | disclosed |
| US-20130296316-A1 | Antiparasitic Agents Based On mTOR Inhibitors | POLLASTRI MICHAEL P (US) | 2013-11-07 | — | — | US | disclosed |
| WO-2012006619-A2 | ANTIPARASITIC AGENTS BASED ON mTOR INHIBITORS | NORTHEASTERN UNIVERSITY (US) | 2012-01-12 | — | — | WO | disclosed |
| US-20110275762-A1 | TRIAZINE, PYRIMIDINE AND PYRIDINE ANALOGS AND THEIR USE AS THERAPEUTIC AGENTS AND DIAGNOSTIC PROBES | UNIVERSITY OF BASEL (CH) | 2011-11-10 | — | — | US | disclosed |
| US-20110275762-A1 | TRIAZINE, PYRIMIDINE AND PYRIDINE ANALOGS AND THEIR USE AS THERAPEUTIC AGENTS AND DIAGNOSTIC PROBES | UNIVERSITY OF BASEL (CH) | 2011-11-10 | — | — | US | disclosed |
| US-20110275762-A1 | TRIAZINE, PYRIMIDINE AND PYRIDINE ANALOGS AND THEIR USE AS THERAPEUTIC AGENTS AND DIAGNOSTIC PROBES | UNIVERSITY OF BASEL (CH) | 2011-11-10 | — | — | US | disclosed |
| EP-2364302-A2 | TRIAZINE, PYRIMIDINE AND PYRIDINE ANALOGS AND THEIR USE AS THERAPEUTIC AGENTS AND DIAGNOSTIC PROBES | University of Basel (CH) | 2011-09-14 | — | — | EP | disclosed |
| WO-2010052569-A2 | TRIAZINE, PYRIMIDINE AND PYRIDINE ANALOGS AND THEIR USE AS THERAPEUTIC AGENTS AND DIAGNOSTIC PROBES | UNIVERSITY OF BASEL (CH) | 2010-05-14 | — | — | WO | disclosed |
| WO-2010052569-A2 | TRIAZINE, PYRIMIDINE AND PYRIDINE ANALOGS AND THEIR USE AS THERAPEUTIC AGENTS AND DIAGNOSTIC PROBES | UNIVERSITY OF BASEL (CH) | 2010-05-14 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110275762-A1 | TRIAZINE, PYRIMIDINE AND PYRIDINE ANALOGS AND THEIR USE AS THERAPEUTIC AGENTS AND DIAGNOSTIC PROBES | MTOR, PIK3CA, PIK3CD | PIK3CA 2/4885MTOR 1/4885PIK3CG 16/4885 |
| US-20130296316-A1 | Antiparasitic Agents Based On mTOR Inhibitors | MTOR, PIK3CD, PIK3C3 | PIK3CA 17/4885MTOR 1/4885PIK3CG 4/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.